Catherine E. Willoughby
Ph.D., Healthcare Research & Data Analyst, Oncology
Dr. Willoughby is a pharmaceutical industry analyst with more than 10 years of experience in oncology research and drug discovery. She has been the principal author of several market forecasting and competitive intelligence projects for a range of hematological malignancy and solid tumor indications. Prior to joining Clarivate, she was a Sara Borrell Postdoctoral Fellow at IDIBAPS-Hospital Clinic in Barcelona, where she contributed to the preclinical development of treatment combinations to overcome resistance to immune checkpoint inhibitors, and a postdoctoral fellow at IRB Barcelona, where she investigated molecular glue degraders.
She obtained her Ph.D. at Newcastle University in the United Kingdom, where she explored novel therapeutic strategies to treat liver cancer.
Dr. Willoughby also holds a B.Sc. (Honors) in medical biochemistry with industrial experience from the University of Manchester and an M.Res. in cancer research from Newcastle University.
